Sarepta Therapeutics, Inc.
22.02USD
+1.0800 (+5.16%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 843.8M | 1.1B | 1.8B | 1.9B | 1.8B | 1.4B |
| Q1 | 188.8M | 231.5M | 359.5M | 611.5M | 330.5M | — |
| Q2 | 211.2M | 239.0M | 360.5M | 513.1M | 328.7M | — |
| Q3 | 207.8M | 309.3M | 429.8M | 370.0M | 352.9M | — |
| Q4 | 235.9M* | 365.1M* | 658.4M | 442.9M | 351.8M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -8.03 | -5.80 | 2.34 | -7.13 | 4.44 | 2.57 |
| Q1 | -1.20 | -5.86 | .370 | -4.60 | 2.88 | — |
| Q2 | -2.65 | -.270 | .070 | 1.89 | -.050 | — |
| Q3 | -2.94 | -.460 | .340 | -.500 | .420 | — |
| Q4 | -1.25* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| .494* |
| 1.50 |
| -3.93 |
| .167 |
| — |